Abstract
Hormonal therapy plays a central role in the overall treatment strategy of sex-specific cancer. Long before the detection of hormones and hormone receptors, ablation of sex hormone glands became part of the treatment of breast and prostate cancer because, in spite of malignancy, the cell growth retained hormone dependence. Moreover, the demonstration of estrogen and/or progesterone receptors as a predictor for the effectiveness of hormonal manipulations in two-thirds to three- fourths of all breast cancers warranted further research in this field.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104–107, 162–165
Bonneterre J, Coppens H, Mauriac L, Metz M, Rouesse J, Armand JP, Fargeot P, Mathieu M, Tubiana M, Cappelaere P (1985) Aminoglutethimide in advanced breast cancer: Clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day. Europ J Cancer Clin Oncol 21: 1153–1158
Brodie AMH, Garrett WM, Tsai-Morris CH, Wink LC (1984) Aromatase inhibition: a new perspective in the treatment of breast cancer. In: Nagel G A, Santen RJ (eds) Aminoglutethimide as an aromatase inhibitor in the treatment of cancer. 13th International Congress of Chemotherapy, Vienna, Hans Huber, Berne, pp 11–23
Camacho AM, Brough AJ, Cash R, Wilroy RS (1966) Adrenal toxicity associated with the administration of an anticonvulsant drug. J Pediatr 68: 852–853
Cash R, Brough AJ, Cohen MNP, Satoh PS (1967) Aminoglutethimide as an inhibitor of adrenal steroidgenesis: mechanism of action and therapeutic trial. J Clin Endocrinol Metab 27: 1239–1248
Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M, Brodie AMH (1987) 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Tumor Diag Ther 8: 271–273
Foekens JA, Henkelmann MS, Fukkink JF, Blankenstein MA, Klijn JGM (1986) Direct effects of LHRH analogs on tumor cells. Eur J Cancer (abstr III-s) 22: 725
Foekens JA, Henkelmann MS, Bolt-de Vries J, Portengen H, Fukkink JF, Blankenstein MA, van Steenbrugge GJ, Mulder E, Klijn JGM (1987) Direct effects of LHRH analogs on breast and prostatic tumor cells. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Raven, New York, pp 369-380 (Monograph series of the european organization for research on treatment of cancer [EORTC], vol 18 )
Gale KE (1982) Treatment of advanced breast cancer with aminoglutethimide. A 14-year experience. Cancer Res [suppl] 42: 3389s–3396s
Griffiths CT, Hall TC, Saba Z, Barlow JJ, Nevinny HB (1973) Preliminary trial of aminoglutethimide in breast cancer. Cancer 32: 31–37
Harris AL, Dowsett M, Smith IE, Jeffcoate SL (1983) Endocrine effects of low-dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer 47: 621–627
Harris AL, Powles TJ, Smith IE, Coombes RC, Ford HT, Gazet JC, Harmer CL, Morgan M, White M, Parsons CA, McKinna JA (1983) Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. Eur J Cancer Clin Oncol 29: 11–17
Harvey HA, Lipton A, Santen RJ, Escher GC, Hardy MA, Glode LM, Sealoff A, Landau RL, Schneir H, Max DT (1981) Phase II study of a gonadotropin-releasing hormone analogue (Leuprolide) in postmenopausal advanced breast cancer patients. Proc Am Ass Cancer Res Am Soc Clin Oncol (Abstract C-436) 22: 444
Harvey HA, Lipton A, Max DT, Pearlman OHG, Diaz-Perches R, de la Garza J (1984) Effective medical castration produced by the GnRH analog Leuprolide in metastatic breast cancer. Proc Am Soc Clin Oncol (abstr C-435) 3: 111
Henderson IC, Cannelos GP (1980) Cancer of the breast. The past decade: Part 1. New Engl J Med 302: 17–30
Höffken K, Kempf H, Miller AA, Miller B, Schmidt CG, Faber P, Kley HK (1986) Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. Cancer Treat Rep 70: 1153–1157
Höffken K, Miller AA, Miller B, Becher R, Aulbert E, Hoffmann B, Anders CU, Callies R, Schmidt CG (1986) Niedrigdosierte Aminoglutethimid-Therapie ohne Cortisolsubstitution beim metastasierenden Mammakarzinom in der Postmenopause. Med Klin 81: 638–642
Höffken K, Jonat W, Possinger K, Kölbel M, Kunz T, Becher R, Callies R (1988) Aromatase inhibition with 4-hydroxyandrostenedione (4-OHA) in treatment of postmenopausal advanced breast cancer (BC). Verh Dtsch Krebsgesellschaft (to be published)
Höffken K, Oesterdickhoff C, Becher R, Callies R, Kurschel E, Anders CU, Scheulen ME, Schmidt CG (1989) LH-RH agonist treatment with Buserilin in premenopausal patients with advanced breast cancer: a phase II study. Cancer Ther Contr 1: (in press)
Hoogstraten B, Gad-el-Mawla N, Maloney TR, Fletcher WS, Vaughn CB, Tranum BL, Athens JW, Costanzi JJ, Foulkes M (1984) Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group Study. Cancer 54: 2248–2256
Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahmann DL, Chang MN, Bisel HF, Windschitl HE, Twito DI, Pfeifle DM (1986) Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 178–185
Klijn JGM, de Jong FH (1982) Treatment with a luteinising hormone-releasing hormone ana-logue (Buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1: 1213–1216
Klijn JGM, de Jong FH, Lamberts SWJ, Blankenstein MA (1985) LHRH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23: 867–873
Klijn JGM, Paridaens R, Foekens JA (eds) (1987) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Raven, New York, ( Monograph series of the european organization for research on treatment of cancer [EORTC]. vol 18 )
Klijn JGM, de Jong FH (1987) Long-term LHRH-agonist (Buserelin) treatment in metastatic premenopausal breast cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Raven, New York, pp 343–352 (Monograph series of the european organization for research on treatment of cancer [EORTC], vol 18 )
Miller AA, Miller BE, Höffken K, Schmidt CG (1987) Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. Cancer Chemother Pharmacol 20: 337–341
Miller AA, Miller BE, Höffken K, Schmidt CG (1987) Conventional-dose aminoglutethimide without hydrocortisone replacement in patients with postmenopausal breast cancer: serum Cortisol levels and response to ACTH stimulation. J Exp Clin Cancer Res 16: 135–138
Murray R, Pitt P (1985) Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. Eur J Cancer Clin Oncol 21: 19–22
Nicholson RI, Maynard PV (1979) Anti-tumour activity of ICI118630, a new potent luteinizing hormone-releasing hormone agonist. Br J Cancer 39: 268–273
Plowman PN, Nicholson RI, Walker KJ (1986) Remissions of metastatic breast cancer in post-menopausal women with luteinising hormone releasing hormone (ICI 118630) therapy. Eur J Cancer (abstract 111–18 ) 22: 746
Pritchard KI, Thomson DB, Myers RE, Sutherland DJA, Mobb BG, Meakin JW (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787–796
Santen RJ, Santner S, Davis B (1978) Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 47: 1257–1265
Santen RJ, Worgul TJ, Samojlike E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA (1981) A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305: 545–551
Schally AV, Redding TW, Comaru-Schally AM (1984) Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep 68: 281–289
Schinzinger AS (1889) Uber Carcinoma mammae. Zentralbl Chir [Suppl] 16: 55–56
Stuart-Harris RC, Smith IE (1984) Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 11: 189–204
Stuart-Harris RC, Dowsett M, Bozek T, McKinna JA, Gazet JC, Jeffcoate SL, Kurkure A, Carr L, Smith IE (1984) Low-dose aminoglutethimide in treatment of advanced breast cancer. Lancet 2: 604–607
Waxman JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, Powles T, Lister TA (1985) The treatment of postmenopausal women with advanced breast cancer with Buserelin. Cancer Chemother Pharmacol 15: 171–173
Williams MR, Walker KJ, Turkes A, Blarney RW, Nicholson RI (1986) The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53: 629–636
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Höffken, K. (1989). New Approaches in the Hormonal Therapy of Breast Cancer. In: Beger, H.G., Büchler, M., Reisfeld, R.A., Schulz, G. (eds) Cancer Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73721-3_33
Download citation
DOI: https://doi.org/10.1007/978-3-642-73721-3_33
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73723-7
Online ISBN: 978-3-642-73721-3
eBook Packages: Springer Book Archive